Exicure: Gains on fast-track tag for potential skin cancer drug

Exicure

11/01/2021 12:58

** Shares of biotechnology firm  XCUR.O  jump 5% to $2.10 in
premarket trade
    ** U.S. FDA grants fast-track tag for co's drug cavrotolimod
(AST-008) for two development programs. Cavrotolimod is made to
activate a patient's immune systems to potentially induce
anti-cancer immune responses
    ** The drug in combination with other therapies will be used
to treat two types of skin cancer
    ** "These Fast Track designations underscore the pressing
need to develop new therapies to treat refractory non-melanoma
skin cancers." - associate professor at University of Washington
Shailender Bhatia

 (Reporting by Sanjana Shivdas in Bengaluru)
 ((SanjanaSitara.Shivdas@thomsonreuters.com; within U.S. +1 646
223 8780, outside U.S. +91 80 6749 1642; Twitter:
@SanjanaShivdas;))